Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 8:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Single consent Clear all
Not listed Not applicable Interventional

Leo Study Unstable Asthma

NCT05308277
View directory record Official record
Conditions
Asthma in Children
Interventions
Leo device monitoring
Device
Lead sponsor
ResMed
Industry
Eligibility
2 Years to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 25, 2022 · Synced Sep 13, 2026, 8:42 AM EDT
Recruiting No phase listed Observational

Prospective Evaluation of Disparities in Provision of Allogeneic Transplantation

NCT06450353
View directory record Official record
Conditions
Allogeneic Transplantation
Interventions
Patient Ancestry Questionnaires
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 13, 2026, 8:42 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Guardant Shield Colorectal Cancer Screening

NCT07436637
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Screening Reminder, Blood Sample Collection
Behavioral · Procedure
Lead sponsor
University of Miami
Other
Eligibility
45 Years to 85 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 13, 2026, 8:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Decreasing Body Dissatisfaction in Male College Athletes: A Randomized Controlled Trial of the Male Athlete Body Project

NCT04077177
View directory record Official record
Conditions
Health Behavior
Interventions
Male Athlete Body Project
Behavioral
Lead sponsor
Illinois Institute of Technology
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 27, 2020 · Synced Sep 13, 2026, 8:42 AM EDT
Terminated Phase 1Phase 2 Interventional

A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101)

NCT04009681
View directory record Official record
Conditions
Metastasis
Interventions
THOR-707, Checkpoint inhibitor, anti-EGFR antibody
Drug
Lead sponsor
Synthorx, Inc, a Sanofi company
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
7
States / cities
Scottsdale, Arizona • Denver, Colorado • Sarasota, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Sep 13, 2026, 8:42 AM EDT
Terminated Phase 3 Interventional Results available

Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial

NCT01285557
View directory record Official record
Conditions
Metastatic Diffuse Gastric Cancer Including Carcinoma of the Gastro-esophageal Junction
Interventions
S-1 (Tegafur+Gimeracil+Oteracil) /cisplatin (investigational arm), Fluorouracil/cisplatin (control arm)
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
4
States / cities
Alexandria, Louisiana • Albuquerque, New Mexico • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 13, 2026, 8:42 AM EDT
Terminated Early Phase 1 Interventional

The Use of Sensory or Motor Cues Using Electrical Stimulation to Reduce Gait Freezing in Patients With Parkinson Disease

NCT00762814
View directory record Official record
Conditions
Parkinson Disease
Interventions
Gait tests with and without the use of a tactile sensory cue (electrical stimulation using a TENS unit)
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
50 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 10, 2018 · Synced Sep 13, 2026, 8:42 AM EDT
Completed Not applicable Interventional

Opting In vs Opting Out

NCT01233804
View directory record Official record
Conditions
Influenza Vaccination
Interventions
Opting Out
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older · Female only
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Galveston, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 30, 2018 · Synced Sep 13, 2026, 8:42 AM EDT
Terminated Phase 2 Interventional Results available

Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors

NCT02706626
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
brigatinib
Drug
Lead sponsor
Criterium, Inc.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
4
States / cities
Denver, Colorado • Durham, North Carolina • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Sep 13, 2026, 8:42 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events

NCT06500884
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Talquetamab, Prophylaxis A, Prophylaxis B, Prophylaxis C, Prophylaxis D, Ramantamig
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
9
States / cities
San Francisco, California • Denver, Colorado • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 13, 2026, 8:42 AM EDT
Completed Phase 1 Interventional

Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies

NCT02270788
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Crenolanib, Sorafenib, methotrexate, hydrocortisone and cytarabine with leucovorin
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
1 Year to 39 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 2, 2017 · Synced Sep 13, 2026, 8:42 AM EDT
Terminated Not applicable Interventional Results available

Anti-inflammatory Treatment at the Onset of Necrotizing Enterocolitis (NEC) in Preterm Infants

NCT01156480
View directory record Official record
Conditions
Necrotizing Enterocolitis
Interventions
hydrocortisone, placebo
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
0 Days to 6 Months
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Chicago, Illinois • Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 8, 2020 · Synced Sep 13, 2026, 8:42 AM EDT
Not yet recruiting Phase 3 Interventional

A Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis

NCT06989567
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
L-citrulline, Placebo
Drug · Other
Lead sponsor
Asklepion Pharmaceuticals, LLC
Industry
Eligibility
6 Years to 21 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Coral Gables, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Sep 13, 2026, 8:42 AM EDT
Completed Phase 2 Interventional Results available

Nivolumab for Recurrent or Progressive IDH Mutant Gliomas

NCT03557359
View directory record Official record
Conditions
Gliomas
Interventions
Nivolumab
Drug
Lead sponsor
Fabio Iwamoto, MD
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
4
States / cities
Miami, Florida • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 13, 2026, 8:42 AM EDT
Completed Phase 2 Interventional Results available

MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma

NCT02724020
View directory record Official record
Conditions
Clear-cell Metastatic Renal Cell Carcinoma
Interventions
Everolimus, MLN0128, MLN1117
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
7
States / cities
Los Angeles, California • Venice, Florida • West Palm Beach, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2021 · Synced Sep 13, 2026, 8:42 AM EDT
Completed Phase 1 Interventional

Treatment Plan for an Individual Patient With Pasireotide for Hyperinsulinemic Hypoglycemia

NCT03103009
View directory record Official record
Conditions
Hyperinsulinemic Hypoglycemia, Post Gastrointestinal Tract Surgery Hypoglycaemia
Interventions
Pasireotide
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Sep 13, 2026, 8:42 AM EDT
Recruiting Not applicable Interventional

Improving Mental Health Treatment for Individuals in Crisis Interacting With the Criminal-Legal System

NCT06564948
View directory record Official record
Conditions
Suicide Risk, Psychiatric Disorders
Interventions
Treatment as usual (TAU), FSJS, FSJS+Navigator Intervention
Other
Lead sponsor
Cambridge Health Alliance
Other
Eligibility
18 Years to 100 Years
Enrollment
1,040 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 13, 2026, 8:42 AM EDT
Completed Not applicable Interventional

HIV Risk and Prevention in Women

NCT02263391
View directory record Official record
Conditions
HIV
Interventions
Opt-in or Opt-out testing, Focus Group
Behavioral
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Feb 22, 2017 · Synced Sep 13, 2026, 8:42 AM EDT
Completed Phase 4 Interventional Results available

Intrapleural Fibrinolytic Therapy to Enhance Chemical Pleurodesis Enhance Chemical Pleurodesis

NCT04806373
View directory record Official record
Conditions
Pleural Effusion
Interventions
Cathflo Activase, Talc Slurry Pleurodesis
Drug
Lead sponsor
Memorial Healthcare System
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Hollywood, Florida
Source: ClinicalTrials.gov public record
Updated Jun 7, 2025 · Synced Sep 13, 2026, 8:42 AM EDT
Not listed Not applicable Interventional

STIMFIX Trail Lead Anchor System for Dorsal Column Stimulator Trail Leads (SECURE Study)

NCT05651646
View directory record Official record
Conditions
Pain
Interventions
Intervention Arm (STIMFIX)
Other
Lead sponsor
STIMFIX
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Lake Havasu City, Arizona • Los Angeles, California • Clifton, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 14, 2022 · Synced Sep 13, 2026, 8:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Promotora Navigator - Culturally Appropriate Patient Navigator

NCT03557801
View directory record Official record
Conditions
Breast Cancer, Screening Mammography, Community Health Worker
Interventions
Mammography with Community Health Worker (individual), Mammography with Community Health Worker (group), Standard of Care Mammography
Behavioral · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
40 Years to 64 Years · Female only
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Sep 13, 2026, 8:42 AM EDT
Completed No phase listed Observational

Usability, Adherence and Diagnostic Performance of PointCheck in Pediatric Population

NCT04889937
View directory record Official record
Conditions
Hematologic Malignancy
Interventions
PointCheck
Device
Lead sponsor
Leuko Labs, Inc.
Industry
Eligibility
7 Years to 39 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Sep 13, 2026, 8:42 AM EDT
Completed Phase 1 Interventional

A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer.

NCT05938270
View directory record Official record
Conditions
Prostate Cancer
Interventions
Saruparib (AZD5305), Darolutamide, No Treatment
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Male only
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Detroit, Michigan • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 13, 2026, 8:42 AM EDT
Terminated Not applicable Interventional Results available

The Effect of Sodium Thiosulfate Eardrops on Hearing Loss in Patients Who Receive Cisplatin Therapy

NCT01369641
View directory record Official record
Conditions
Cancer
Interventions
Insertion of Pressure Equalization (PE) Tubes, Sodium Thiosulfate (STS), Saline (Placebo), Cisplatin
Procedure · Drug · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Sep 13, 2026, 8:42 AM EDT